Isoprenaline (ISO) at high doses can cause severe stress to myocardium resulting in an infarct-like necrosis in rats. However, its effects at repeatedly low dose exposure on heart, kidney and aorta are still unclear. Hence, this study was aimed to investigate the effects of repeated administration of low dose ISO on the organs in rats by using Langendorff-perfused isolated hearts, ELISA kits, qPCR and histopathology techniques. Male Wistar rats (n=24) were randomly divided into three groups which were given 5 or 10 mg/kg/day of ISO (ISO 5 and ISO 10, respectively), or normal saline (control) subcutaneously for 14 days. Blood pressure was recorded at day-0, 7 and 14. Heart, aorta, kidneys, and blood were then collected. ISO at both doses significantly increased the heart weight and blood pressure (p<0.05), while the heart rate was significantly decreased (p<0.05). ISO also increased serum troponin and NT-pro-BNP, and decreased vascular relaxation dose-dependently. Group ISO 10 showed significantly increased cardiomyocyte area and cardiac collagen content, as well as reduced serum nitrite (p<0.05). However, ISO at both doses did not affect the cardiac mechanical function, renal oxidative stress, inflammation, as well as renal gene expressions of angiotensin-converting enzyme and angiotensin II type 1 receptor. In conclusion, repeated low dose of ISO significantly causes myocardial injury and reduces vascular function in rats. The findings imply that this rat model could be a suitable model of heart injury without the complication of renal injury.
Background: Cardiac glycosides such as digoxin have been commonly used for patients with heart failure; however, their toxicity remains a main concern. 17βH-neriifolin (SNA209), a cardiac glycoside compound, has been recently isolated from Ceberra odollum Gaertn and was shown to improve the heart’s pumping ability in failing hearts ex vivo. Thus, this study aimed to investigate the potential use of SNA209 as a treatment for isoprenaline (ISO)-induced heart failure in rats. Methods: Forty male Wistar rats were randomly divided into five groups. Heart failure was induced by isoprenaline (ISO, 10 mg/kg/s.c) for 14 days daily, followed by SNA209 treatment (5 mg/kg; p.o) for another 14 days daily. Control rats were given saline as a vehicle for ISO and DMSO as a vehicle for SNA209. Results: Systolic and diastolic blood pressure (SBP and DBP) in all ISO-treated groups were significantly increased compared to the control group (p < 0.05), and SNA209 treatment managed to reduce the SBP and DBP. Additionally, SNA209 treatment significantly increased the heart rate and normalized the ECG parameters in ISO-treated rats. Pro-B-type natriuretic peptide and troponin T level, a cardiac injury markers, was remarkably reduced by SNA209 in the ISO-treated group. Cardiac hypertrophy was evident in increased cardiomyocyte size in ISO groups; however, SNA reduced the cardiomyocyte size. The left ventricular developed pressure (LVDP) in ISO treated with SNA209 was significantly raised, indicating a chronotropic effect. Cardiac Na+/K+-ATPase expression of the α1 subunit, sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a (SERCA2a), and sodium–calcium exchanger subunit were significantly increased in the SNA treatment groups. Conclusions: The SNA 209 treatment improved cardiac function and structure, likely via modulating intracellular calcium management, so underscoring its potential as an adjuvant therapy for heart failure.
Background: Oxidative stress and maladaptive cardiac remodeling are key contributors to heart failure progression. Xestospongia testudinaria, a marine sponge rich in bioactive compounds, possesses antioxidant and lipid-modulating properties. This study investigated the cardioprotective and antioxidant effects of Xestospongia testudinaria methanolic extract (Xesto) in an isoprenaline-induced rat model of heart failure. Methods: Thirty-five healthy male Wistar rats weighing 200–250 g were used in this study. Heart failure was induced in rats via subcutaneous administration of isoprenaline (10 mg/kg/day) for 14 days. Rats were subsequently treated with Xesto (15 mg/kg/day, oral gavage), digoxin (10 mg/kg/day), or saline for an additional 14 days. Hemodynamic parameters, serum NT-proBNP, oxidative stress biomarkers, biochemical indices, hematological parameters, and histopathological changes were evaluated. Molecular docking was performed to assess the interaction of Xesto constituents with Kelch-like ECH-associated protein 1 (KEAP1). Results: Isoprenaline administration significantly increased blood pressure, NT-proBNP, malondialdehyde, hepatic enzymes, and urea levels, while reducing superoxide dismutase and catalase activities. Xesto treatment significantly improved hemodynamic parameters, restored antioxidant enzyme activities, reduced lipid peroxidation, and normalized biochemical and hematological alterations. Histological analysis demonstrated reduced cardiomyocyte hypertrophy and collagen deposition in Xesto-treated rats. Docking analysis showed favorable binding of trans-phytol within the KEAP1 Kelch domain, suggesting possible modulation of antioxidant regulatory pathways. Conclusions: Xestospongia testudinaria exhibited significant cardioprotective and antioxidant effects in isoprenaline-induced heart failure, potentially through enhancement of endogenous antioxidant defenses and attenuation of pathological cardiac remodeling. These findings support its potential as a marine-derived therapeutic candidate for oxidative stress-associated cardiovascular disorders.